Kilitch Drugs India reported an 18.7% rise in FY26 revenue to ₹235.47 crore and an 18.3% increase in net profit to ₹29.50 crore. The company also commissioned a new manufacturing facility in Maharashtra, designed to meet global regulatory standards.
Kilitch Drugs India: FY26 Financials Show Strong Growth, New Facility Operational
FY26 Revenue: ₹235.47 crore; FY26 Net Profit: ₹29.50 crore. Reader Takeaway: Steady growth and expansion into regulated markets are positive; compliance and interest coverage require monitoring. ## What just happened Kilitch Drugs India has announced its financial results for the fiscal year ending March 2026. The company reported a consolidated revenue from operations of ₹235.47 crore, an increase from ₹198.32 crore in the previous fiscal year. Net profit from continuing operations grew to ₹29.50 crore from ₹24.94 crore in FY25. Additionally, the company has successfully commissioned its new greenfield manufacturing facility in Pen, Maharashtra. ## Why this matters The financial performance indicates a positive growth trajectory for Kilitch Drugs. The commissioning of the new facility, designed to meet stringent global standards like WHO, EU-GMP, and USFDA, is a significant step towards expanding its international market presence and diversifying manufacturing capabilities. This could lead to higher export revenues and improved profitability in the long term. ## The backstory The company's recent corporate actions include a rights issue approved in July 2025 and a bonus issue of 1.74 crore shares in March 2026. These actions reflect efforts to strengthen the capital base and reward existing shareholders. ## What changes now With the new facility operational, Kilitch Drugs is better positioned to tap into regulated international markets. This expansion is expected to drive future revenue growth and potentially enhance operational efficiencies. The company also reported a strong Operating Profit Margin of 52.87% for the year. ## Risks to watch Despite the positive financial results, concerns remain. The company paid fines to BSE and NSE in August 2025 for a non-compliance issue regarding prior intimation for a board meeting. Furthermore, the Interest Coverage ratio has declined to 0.42 as of March 31, 2026, from 0.71 in the prior year, which could indicate increased financial strain or higher debt servicing costs relative to earnings. ## Peer comparison While specific peer data is not provided in the filing, the company's focus on expanding into regulated markets like those adhering to USFDA and EU-GMP standards suggests an ambition to compete with established players in the pharmaceutical export segment. ## Context metrics (time-bound) * Revenue from Operations grew 18.7% year-on-year to ₹235.47 crore in FY26. * Net Profit from Continuing Operations increased 18.3% year-on-year to ₹29.50 crore in FY26. * A bonus issue of 1:1 was completed in March 2026. * The Interest Coverage ratio stood at 0.42 as of March 31, 2026. ## What to track next Investors will be keen to observe the revenue contribution from the new Pen facility and its impact on overall margins. Monitoring the company's compliance adherence and any further changes in its interest coverage ratio will also be crucial.
